Back

Phase 1 safety, tolerability, and pharmacokinetics of NS-863 supporting development for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease

31 August 2026 (10:15 - 11:00)
Organised by: Logo
Congress Presentation Part of: Pulmonary hypertension and right ventricular Pulmonary Hypertension ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Professor Yuichi Tamura

IUHW Mita Hospital, Tokyo (Japan)

5 More presentations in this session

Presentation thumbnail
Characterization of coronary microvascular dysfunction in patients with pulmonary hypertension
Doctor O. Velollari (Mainz, DE)
Abstract
Presentation thumbnail
Effects of high-intensity inspiratory muscle training on inspiratory muscle strength and exercise capacity in pulmonary arterial hypertension
Ms P. Wu (Taipei, TW)
Abstract
Presentation thumbnail
A CT echo triage model predicts markedly elevated pulmonary vascular resistance and right ventricular failure phenotype at catheterization
Doctor M. Al-Sarmi (Dublin, IE)
Abstract
Presentation thumbnail
Beyond hypocapnia: standardised capillary oxygen partial pressure predicts risk and treatment response in PAH
Mr T. Kramer (Cologne, DE)
Abstract
Presentation thumbnail
Diabetes is associated with reduced survival in controls but not in patients with idiopathic pulmonary arterial hypertension
Associate Professor B. Kjellstrom (Lund, SE)
Abstract

Access the full session

Session thumbnail
Pulmonary hypertension and right ventricular

The Event

Event poster

ESC Congress 2026

31 August 2026 10:15 CET
You may be interested in
thumbnail
Congress Presentation
Safety, tolerability, and pharmacokinetics (PK) of treprostinil palmitil inhalation powder (TPIP): a phase 1, randomised, double-blind, single- and multiple-dose study
30 August 2021
thumbnail
Congress Presentation
AD-9308 ameliorates the impacts of 4-HNE on the progress of pulmonary arterial hypertension in aldehyde dehydrogenase 2*1*2 knock-in mice
26 August 2022
thumbnail
Congress Presentation
Rationale and design of the CADENCE trial: evaluating sotatercept in Cpc-PH secondary to HFpEF
1 September 2025
thumbnail
Congress Presentation
Twenty-year experience and outcomes in a national paediatric pulmonary hypertension service
30 August 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources